Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society

Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic
Constipation at Annual Meeting of the Swiss Society of Gastroenterology

BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly
owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"),
announced today that it will present four posters evaluating the overall
efficacy and tolerability of AMITIZA® (lubiprostone) as a treatment for
chronic idiopathic constipation (CIC). These posters contain data
demonstrating the efficacy and tolerability of AMITIZA regardless of age,
gender, and race, a pooled analysis of the most frequent adverse events
associated with AMITIZA, and an evaluation of the efficacy of AMITIZA in
patients suffering from refractory constipation. Sucampo will present these
data during the Annual Meeting of the Swiss Society of Gastroenterology in
Basel, Switzerland on Friday, September 13, 2013.

"AMITIZA has been proven to be effective in treating a wide range of patients
suffering from CIC," said Ryuji Ueno, MD, PhD, PhD, SAG's President and Chief
Scientific Officer. "We are excited to present these data on AMITIZA, the
world's first chloride channel activator, to gastroenterologists in
Switzerland."

AMITIZA increases intestinal fluid secretion, softens stools and increases
motility in the intestine, thereby facilitating the passage of stool and
alleviating symptoms associated with CIC.

The following posters will be presented between 1:30-2:00 p.m. CEST (7:30-8:00
a.m. ET) at the Annual Meeting of the Swiss Society of Gastroenterology at the
Basel Congress Center in Basel, Switzerland on Friday, September 13, 2013:

  *Long-Term Efficacy of Lubiprostone Demonstrated in Patients with
    Constipation Regardless of Age, Gender or Race

    *Taryn R. Joswick, BS, PMP, Gayle R. Dolecek, PD, MPH, Peter Lichtlen MD,
      PhD, Ryuji Ueno, MD, PhD, PhD, Poster G9

  *Lubiprostone Treatment Improves Constipation and Related Symptoms in
    Patients Refractory to Other Constipation Therapies

    *Taryn R. Joswick, BS, PMP, Raymond M. Panas, PhD, Peter Lichtlen MD,
      PhD, Ryuji Ueno, MD, PhD, PhD, Poster G10

  *Lubiprostone Demonstrates Efficacy in Adult Patients with Constipation
    Regardless of Age, Gender or Race

    *Taryn Joswick, BS, PMP, Gayle R. Dolecek, PD, MPH, Raymond M. Panas PhD,
      Ryuji Ueno, MD, PhD, PhD, Poster G11

  *Pooled Analysis of the Most Frequent Adverse Events Associated with the
    Use of Lubiprostone

    *Taryn R. Joswick, BS, PMP, Gayle R. Dolecek, PD, MPH, Ryuji Ueno, MD,
      PhD, PhD, Poster G12

Sucampo will also be present in the exhibition hall with a booth located at
E38.

Additional information about the Annual Meeting of the Swiss Society of
Gastroenterology can be found at http://www.sgg-sgvc-congress.ch/.

About AMITIZA

AMITIZA (lubiprostone) capsules are indicated in Switzerland for the treatment
of chronic idiopathic constipation (CIC) in adults aged 18 and above. Sucampo
began active commercialization of AMITIZA in Switzerland for CIC in the second
quarter of 2013.

Short Prescribing Information (Switzerland)

Before prescribing AMITIZA please consult the full Prescribing Information
(www.swissmedicinfo.ch). Composition: Soft capsule, 24 µg lubiprostone.
Indication: treatment of chronic idiopathic constipation in adults aged 18 and
above. Dosage: One 24 µg capsule should be taken twice daily with food. The
need for continued therapy must be assessed at regular intervals by stopping
treatment. Contraindication: must not be used for patients with a medical
history of known or suspected mechanical gastrointestinal obstructions or with
known oversensitivity to the active ingredient or one of the excipients.
Precaution: Patients may experience nausea. If this occurs, concomitant
administration of food may reduce symptoms. AMITIZA should not be prescribed
to patients that have severe diarrhoea. Patients should be aware of the
possible occurrence of diarrhoea during treatment and inform their health care
provider if diarrhoea becomes severe. No dosage adjustment is required for
patients with mild hepatic impairment. For patients with moderate to severe
hepatic impairment (Child-Pugh classification B or C), the initial dosage
should be decreased to 24 micrograms (1 capsule once a day with breakfast or
supper). If the initial dose is tolerated and an adequate response has not
been obtained after an appropriate interval, the dose can be increased to full
dosing (one capsule twice daily) with appropriate monitoring of patient
response. Patients may experience dyspnea within an hour of first dose. This
symptom generally resolves within hours, but may recur with repeat dosing.
Patients who experience dyspnea should inform their doctor. Interaction: It is
unlikely that lubiprostone will cause interactions with other medications.
Pregnancy and lactation: AMITIZA should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. Breast-feeding
during use of AMITIZA is not recommended. Side effects: Most common in
clinical studies (in over 10% of patients) were nausea, diarrhoea and
headaches. Other side effects (in over 1% of patients) were abdominal pain,
abdominal distension, flatulence, vomiting, dizziness, peripheral oedema,
fatigue, chest discomfort or pain, dyspnea, abdominal discomfort, dyspepsia,
and dry mouth. Although dyspnea is not classified as severe, some patients
discontinued treatment. Packaging: Soft capsules in HDPE bottles of 56 (B)
with seal and rayon filler. State of information: May 2013. Sucampo AG, Zug.

About Sucampo

Sucampo AG, based in Zug, Switzerland, is a wholly-owned subsidiary of Sucampo
Pharmaceuticals, Inc., a global biopharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please
visit www.sucampo.com.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or regulatory
actions. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk factors
and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which
Sucampo incorporates by reference.

Follow us on Twitter (@Sucampo_Pharma). Follow us on Linkedin (Sucampo
Pharmaceuticals).

Twitter LinkedIn

CONTACT: Silvia Taylor
         Senior Vice President, IR, PR,
         and Corporate Communications
         1-240-223-3718
         staylor@sucampo.com

Sucampo Logo
 
Press spacebar to pause and continue. Press esc to stop.